| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT05456191 A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib… |
Primary endpoint(s) modified |
| 2026-05-15 | NCT05554341 Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-05-15 | NCT05554341 Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT04877522 | Asciminib Roll-over Study | Chronic Myelogenous Leukemia | Recruiting |
| Phase 3 | |||
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib… | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Active, Not Recruiting |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+… | Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Active, Not Recruiting |
| Phase 2 | |||
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced… | Advanced Malignant Solid Neoplasm | Recruiting |
| NCT07493408 | Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem… | Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Not Yet Recruiting |
| NCT03516279 | Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With… | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Active, Not Recruiting |
| NCT05554341 | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane… | Metastatic Malignant Solid Neoplasm | Active, Not Recruiting |
| Phase 1 | |||
| NCT04903119 | Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | Metastatic Melanoma | Recruiting |